Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nuvasive Inc (NUVA)

Nuvasive Inc (NUVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,064,793
  • Shares Outstanding, K 52,046
  • Annual Sales, $ 1,102 M
  • Annual Income, $ 12,480 K
  • 60-Month Beta 1.19
  • Price/Sales 3.59
  • Price/Cash Flow 15.32
  • Price/Book 4.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.63
  • Number of Estimates 9
  • High Estimate 0.66
  • Low Estimate 0.61
  • Prior Year 0.69
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.02 +4.11%
on 01/03/20
81.91 -4.65%
on 01/15/20
+1.55 (+2.02%)
since 12/17/19
3-Month
64.35 +21.37%
on 10/18/19
81.91 -4.65%
on 01/15/20
+12.81 (+19.62%)
since 10/17/19
52-Week
45.60 +71.27%
on 01/23/19
81.91 -4.65%
on 01/15/20
+31.22 (+66.60%)
since 01/17/19

Most Recent Stories

More News
NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show

NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.

HAE : 113.85 (-1.86%)
HRC : 115.75 (-0.51%)
NUVA : 78.10 (-1.59%)
MDT : 119.03 (+0.14%)
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

XENT : 24.45 (-1.93%)
NUVA : 78.10 (-1.59%)
EXAS : 88.06 (-1.92%)
OGI : 3.26 (-4.12%)
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

XENT : 24.45 (-1.93%)
NUVA : 78.10 (-1.59%)
EXAS : 88.06 (-1.92%)
OGI : 3.26 (-4.12%)
Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?

Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.

XENT : 24.45 (-1.93%)
NUVA : 78.10 (-1.59%)
EXAS : 88.06 (-1.92%)
APHA : 5.27 (+1.54%)
NuVasive Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue Results

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced preliminary...

NUVA : 78.10 (-1.59%)
Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?

Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.

XENT : 24.45 (-1.93%)
NUVA : 78.10 (-1.59%)
EXAS : 88.06 (-1.92%)
APHA : 5.27 (+1.54%)
NuVasive to Participate in 38th Annual J.P. Morgan Healthcare Conference

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management...

JPM : 138.20 (+0.69%)
NUVA : 78.10 (-1.59%)
NuVasive Appoints Matthew K. Harbaugh as Chief Financial Officer

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment...

NUVA : 78.10 (-1.59%)
Bio-Rad Gains on New Product Portfolio Despite Currency Woes

Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.

OMCL : 85.93 (-1.82%)
BIO : 376.89 (-0.74%)
HAE : 113.85 (-1.86%)
NUVA : 78.10 (-1.59%)
Here's Why You Should Add NuVasive Stock to Your Portfolio

Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.

MDT : 119.03 (+0.14%)
NUVA : 78.10 (-1.59%)
HAE : 113.85 (-1.86%)
EYE : 32.83 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NUVA with:

Business Summary

NuVasive, Inc. is transforming spine surgery and beyond with minimally invasive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, and software systems for surgical...

See More

Key Turning Points

2nd Resistance Point 81.01
1st Resistance Point 79.56
Last Price 78.10
1st Support Level 77.24
2nd Support Level 76.37

See More

52-Week High 81.91
Last Price 78.10
Fibonacci 61.8% 68.04
Fibonacci 50% 63.76
Fibonacci 38.2% 59.47
52-Week Low 45.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar